Fresenius Kabi's tocilizumab biosimilar Tyenne® is the first and only tocilizumab biosimilar to be launched in Canada and is ...

Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfitm is indicated for the treatment of several serious ...

TORONTO, May 27, 2025 /CNW/ - Fresenius Kabi Canada announces that its ustekinumab ... In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products ...

The positive effect of the Fresenius Medical Care transaction was partially offset by the cash impact from the completed divestment of Vamed international project business. Kabi continued its ...

Report Ocean, a leading strategic consulting and market research firm, in its recent study, expects the India infusion pumps market size to grow at a CAGR of 8.26% during the forecast period between ...

Take Command, a leading health benefits technology company and the largest provider of Individual Coverage Health Reimbursement Arrangements (ICHRAs) in the country, announced that Jamie Potecha has ...

The Business Research Company’s Sarcoidosis Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, May 30, 2025 / EINPresswire.com / -- What Is ...

“We entered 2025 sharply focused on our 5x30 strategy and our transition into an innovative ... the company successfully reached a volume-limited settlement agreement with Fresenius Kabi USA and its ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...